Clarivate Epidemiology's coverage of IBS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of IBS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.
Clarivate Epidemiology's IBS forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IBS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four IBS patient populations, as follows:
Prevalence of Irritable Bowel Syndrome per 100 People Aged 20 or Older in 2021 and 2041tttttttttttt
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Irritable Bowel Syndrome Over the Next 20 Years
Analysis of the Prevalent Cases of Irritable Bowel Syndrome in 2021 by IBS Subtypettttttttt
Epidemiology Data
Methods
Total Prevalent Cases
Irritable Bowel Syndrome Subtypes
Reference Materials
Literature Review
Studies Included in the Analysis of Irritable Bowel Syndrome
Studies Excluded from the Analysis of Irritable Bowel Syndrome
Risk / Protective Factors
Risk / Protective Factors for Irritable Bowel Syndrome
Bibliography
Abbreviations
Glossary
Aishwarya S. Ambat
Aishwarya S. Ambat, M.P.H., is an associate epidemiologist at Clarivate. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.
